At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 315 enrolled
Drug / intervention
Orvepitant Maleate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough
In Brief
A Phase 2 clinical trial evaluating Orvepitant Maleate and Placebo for Chronic Refractory Cough. Completed, enrolled 315 participants across 66 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Refractory Cough
CountriesCanada, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMay 2017
Primary CompletionJan 2019
Study CompletionJan 2019
TodayJul 2026
First PostedDec 15, 2016
Enrollment StartMay 22, 2017
Primary CompletionJan 14, 2019
Study CompletionJan 24, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.5 years ago
Interventions
Orvepitant Maleatedrug
Tablet, once daily, oral
Placebodrug
Tablet, once daily, oral